Effect of 4-[3,5-bis(trimethylsilyl)benzamido] benzoic acid (TAC-101) on the liver metastasis of colon 26-L5 carcinoma cells.
We found that oral administration of the benzoic acid derivative, TAC-101 ¿4-[3,5-bis(trimethylsilyl)benzamido] benzoic acid¿ significantly inhibited experimental liver metastasis of murine colon 26-L5 carcinoma cells, whereas all-trans-retinoic acid (ATRA) did not show any inhibitory effect. Treatment with more than 10 microM TAC-101 for 24 h showed direct cytotoxicity against tumor cells in vitro. In contrast, ATRA did not have any direct cytotoxicity. TAC-101 also inhibited the tumor cell invasion enhanced by TPA (12-O-tetradecanoylphorbol-13-acetate; AP-1 activator) in a concentration-dependent manner, whereas ATRA did not. Furthermore, zymographic analysis revealed that noncytotoxic concentrations (< 10 microM) of TAC-101 inhibited TPA-induced production of urokinase-type plasminogen activator (u-PA) and matrix metalloproteinase (MMP)-9 from tumor cells, which is considered to be associated with their invasive and metastatic potentials. These results suggest that such an inhibitory effect is partly due to the ability of TAC-101 to bind a retinoic acid receptor (RAR)-alpha and consequently inhibit metastasis-related gene transcription by interfering with AP-1/DNA binding, as we showed previously. On the other hand, TAC-101 also inhibited the production of MMP-2, which is not affected by TPA. Therefore, the antimetastatic effect of TAC-101 includes an alternative regulatory mechanism for MMP production. These results indicate that the in vivo antimetastatic effect of TAC-101 is partly due to the cytotoxicity against tumor cells, which may be caused by the induction of apoptosis, and inhibition of the production of invasion-associated proteolytic enzymes.
Sakukawa
R
R
Department of Pathogenic Biochemistry, Research Institute for Wakan-Yaku, Toyama Medical and Pharmaceutical University, Japan.
Murakami
K
K
Ikeda
T
T
Yamada
Y
Y
Saiki
I
I
D000818:Animals; D016588:Anticarcinogenic Agents / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D017209:Apoptosis / Q000187:drug effects; D001565:Benzoates / Q000627:therapeutic use*; D017364:Collagenases / Q000096:biosynthesis; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology*; D005260:Female; D018093:Gelatinases / Q000096:biosynthesis; D008114:Liver Neoplasms, Experimental / Q000517:prevention & control* / Q000556:secondary*; D020778:Matrix Metalloproteinase 2; D020780:Matrix Metalloproteinase 9; D008666:Metalloendopeptidases / Q000096:biosynthesis; D051379:Mice; D008807:Mice, Inbred BALB C; D009361:Neoplasm Invasiveness; D009368:Neoplasm Transplantation; D014212:Tretinoin / Q000627:therapeutic use; D014297:Trimethylsilyl Compounds / Q000627:therapeutic use*; D014407:Tumor Cells, Cultured; D014568:Urokinase-Type Plasminogen Activator / Q000096:biosynthesis
D016588:Anticarcinogenic Agents; D000970:Antineoplastic Agents; D001565:Benzoates; C112689:TAC 101; D014297:Trimethylsilyl Compounds; D014212:Tretinoin; D014568:Urokinase-Type Plasminogen Activator; D017364:Collagenases; D018093:Gelatinases; D008666:Metalloendopeptidases; D020778:Matrix Metalloproteinase 2; D020780:Matrix Metalloproteinase 9